Pramlintide is a lab-made version of amylin, a hormone the pancreas releases together with insulin after meals. It differs from human amylin at three positions, each changed to proline. FDA approved it as Symlin on March 16, 2005, for people with type 1 or type 2 diabetes who use mealtime insulin. Drugs@FDA now lists every Symlin product as discontinued.
Quick answer: Pramlintide is an amylin analog peptide. Pramlintide is FDA-approved as the active ingredient in Symlin, first approved on March 16, 2005. Its labeled use is add-on treatment in type 1 or type 2 diabetes for people using mealtime insulin. Drugs@FDA lists all Symlin products as discontinued, and FDA's NDC Directory gives a marketing end date of January 31, 2027.
Vitrapep does not sell pramlintide; this page is a reference summary of published research and regulatory information.
What is pramlintide and how is it built?
Pramlintide is a synthetic peptide, a short chain of amino acids (see what peptides are). The Symlin label describes it as the acetate salt of a 37-amino-acid polypeptide. It differs from human amylin only by proline at positions 25, 28 and 29, where the hormone has alanine, serine and serine [1].
PubChem's structure record shows a small ring near the start of the chain, closed by a disulfide bond. The final tyrosine carries an amide group [4]. The label reports that the main metabolite, which lacks the first lysine, is biologically active in vitro [1].
What is pramlintide and how is it built
| Property | Pramlintide |
|---|---|
| Class | Amylin analog; a synthetic peptide [1] |
| Changes from human amylin | Proline replaces alanine 25, serine 28 and serine 29 [1] |
| Molecular formula | C171H267N51O53S2 (PubChem CID 70691388) [4] |
| Molecular weight | 3949 g/mol in PubChem; 3949.4 on the label [1], [4] |
| Elimination half-life | About 48 minutes in healthy individuals [1] |
| Plasma binding | About 40% unbound; little binding to albumin or red blood cells [1] |
| US brand and first approval | Symlin, March 16, 2005; a new molecular entity [2], [3] |
| Developer and current holder | Developed by Amylin Pharmaceuticals; NDA 021332 now held by AstraZeneca AB [2], [3] |
| US marketing status | All three Symlin products listed as discontinued [2] |
How was pramlintide developed?
Amylin was identified in 1987 by two groups studying islet amyloid, protein deposits that form in pancreatic islets in type 2 diabetes. Westermark and colleagues purified a 37-residue peptide from human insulinoma and cat islet amyloid. They called it islet amyloid polypeptide and also found it in normal beta cells [5]. Cooper and colleagues in Oxford isolated a 37-amino-acid peptide that was 46% identical to calcitonin gene-related peptide (CGRP) [6].
Pramlintide's proline swaps sit in a region tied to fibril formation. In 1990, Westermark's group showed that positions 25 to 29 of human amylin are strongly amyloidogenic in vitro. A single proline in place of serine 28, as in several rodents, almost completely blocked fibril formation [7]. These were cell-free laboratory experiments, not studies in people.
The Federal Register gives the regulatory timeline. The investigational new drug application took effect on July 24, 1992. Amylin Pharmaceuticals submitted the new drug application on December 8, 2000, and FDA approved it on March 16, 2005 [3]. FDA's Endocrinologic and Metabolic Drugs Advisory Committee was scheduled to discuss it on July 26, 2001 (Federal Register notice).
How does pramlintide work?
Amylin is stored with insulin in pancreatic beta cells and released with it in response to food. The Symlin label notes reduced meal-related secretion of both hormones in type 1 and type 2 diabetes [1].
Nonclinical studies cited on the label describe three actions of amylin. It slows gastric emptying without changing overall nutrient absorption. It suppresses glucagon secretion, which lowers glucose output from the liver. It also regulates food intake through centrally mediated effects on appetite [1]. In human studies, pramlintide slowed gastric emptying, reduced the after-meal rise in glucagon and decreased caloric intake [1]. In label buffet-meal studies, placebo-subtracted caloric intake fell about 21% in type 1 and 23% in type 2 diabetes [1].
Amylin's receptors are unusual. A 1999 cell study by Christopoulos and colleagues paired the calcitonin receptor with receptor activity-modifying proteins (RAMPs). Adding RAMP1 or RAMP3 created amylin binding sites, while RAMP2 did not. A 2015 review by Hay and colleagues says amylin acts mainly in brain areas called circumventricular organs [8].
What is pramlintide approved for?
Section 1 of the Symlin label covers patients with type 1 or type 2 diabetes who use mealtime insulin therapy. It applies when they "have failed to achieve desired glucose control despite optimal insulin therapy" [1]. The 2005 approval added "with or without a concurrent sulfonylurea agent and/or metformin" for type 2 diabetes [3].
Symlin is not approved for weight management. Safety and effectiveness in pediatric patients have not been established [1]. The mealtime insulins it is paired with are covered in Vitrapep's insulin analogs guide. Other approved peptide drugs appear in the list of FDA-approved peptide medicines.
What did the key pramlintide trials show?
The label says 2,333 people with type 1 diabetes and 1,852 with type 2 diabetes received Symlin in controlled trials [1]. Four published randomized, double-blind, placebo-controlled trials show the main findings. In each, pramlintide or placebo was added to existing insulin.
What did the key pramlintide trials show
| Trial | Population and size | Design and length | Main reported results |
|---|---|---|---|
| Whitehouse et al., 2002 [9] | 480 people with type 1 diabetes | 52 weeks, then a one-year open-label extension | HbA1c down 0.67 vs 0.16 points at week 13, difference sustained to week 52; average weight loss |
| Ratner et al., 2004 [10] | 651 people with type 1 diabetes | 52 weeks | HbA1c down 0.29 and 0.34 points in two arms vs 0.04 with placebo; weight down 0.4 kg vs up 0.8 kg |
| Hollander et al., 2003 [11] | 656 people with type 2 diabetes using insulin | 52 weeks | HbA1c down 0.62 points at week 52 in one arm; HbA1c below 8% in 46% vs 28% |
| Edelman et al., 2006 [12] | 296 people with type 1 diabetes | 29 weeks, with insulin lowered at the start and then adjusted | HbA1c down 0.5 points in both groups; lower after-meal glucose; weight down 1.3 kg vs up 1.2 kg |
In the Whitehouse trial, the overall severe hypoglycemia event rate did not rise [9]. In the Edelman trial, nausea occurred in 63% versus 36% [12].
Across the five long-term trials summarized on the label, placebo-subtracted HbA1c reductions at six months ranged from 0.25 to 0.34 percentage points [1]. The trials measured glucose control, weight and safety, not cardiovascular events.
What side effects does the Symlin label list?
Boxed warning. Symlin used with insulin increases the risk of severe hypoglycemia, particularly in type 1 diabetes. When severe hypoglycemia occurs, it is seen within 3 hours after Symlin is given. The label warns of serious injury if it occurs while driving or operating heavy machinery [1]. Symlin alone does not cause hypoglycemia; the increased risk arises in combination with mealtime insulin [1].
The label's six-month type 1 trials did not reduce insulin at the start. In the first three months, 16.8% on Symlin had patient-ascertained severe hypoglycemia, versus 10.8% on placebo. In the type 2 trials, the figures were 8.2% versus 2.1% [1].
Common reactions. The most common reactions, each in at least 5% of patients and more often than placebo, were nausea, vomiting, anorexia and headache. Nausea was more frequent early in treatment and decreased with time in most patients [1].
What side effects does the Symlin label list
| Adverse reaction | Type 1, Symlin, % (N=716) | Type 1, placebo, % (N=538) | Type 2, Symlin, % (N=292) | Type 2, placebo, % (N=284) |
|---|---|---|---|---|
| Nausea | 48 | 17 | 28 | 12 |
| Anorexia | 17 | 2 | 9 | 2 |
| Vomiting | 11 | 7 | 8 | 4 |
| Headache | Not listed | Not listed | 13 | 7 |
| Fatigue | 7 | 4 | 7 | 4 |
| Inflicted injury | 14 | 10 | Not listed | Not listed |
Source: Symlin label, Tables 1 and 2; all groups also used insulin [1]. "Not listed" means the reaction did not meet the label's listing threshold in that population, not that it never occurred.
Contraindications and warnings. Symlin is contraindicated with serious hypersensitivity to the product, hypoglycemia unawareness or confirmed gastroparesis. Because it slows gastric emptying, it may delay absorption of oral medicines [1]. Postmarketing reports include injection site reactions and pancreatitis; their frequency cannot be reliably estimated [1].
Animal findings. Two-year studies in mice and rats found no drug-induced tumors. Rat studies found increased congenital abnormalities in fetuses, while rabbit studies did not. Human pregnancy data are not sufficient to determine a drug-associated risk [1].
What other research has studied pramlintide?
Obesity. Pramlintide was tested for weight loss but never approved for it. In a 16-week phase 2 trial, Aronne and colleagues randomized 204 adults with obesity who were not using insulin. Completers had a placebo-corrected weight reduction of 3.7%. Smith and colleagues randomized 411 adults with obesity alongside a lifestyle program. At month 12, 40% and 43% in two pramlintide arms had lost at least 10% of body weight, versus 12% on placebo. Only 146 people were evaluable at month 12 [13].
The Hay review notes that amylin agonists looked most useful for weight loss in combination with other agents [8]. The leading current example is cagrilintide, a long-acting amylin analog paired with semaglutide. See Vitrapep's cagrilintide guide and CagriSema trial summary.
Automated insulin delivery. In a 2020 randomized crossover trial (NCT02814123), McGill researchers tested a dual-hormone closed-loop system in adults with type 1 diabetes. Time in the target glucose range rose from 74% with rapid insulin alone to 84% with rapid insulin plus pramlintide. A 26-person outpatient study of a similar approach is registered as NCT07914621.
Migraine. In a 2021 crossover trial, 36 people with migraine without aura were enrolled to receive pramlintide or human alpha-CGRP on separate days. Migraine-like attacks followed in 41% after pramlintide and 56% after CGRP. A follow-up trial is registered as NCT07340788. Vitrapep explains how to find a peptide clinical trial.
What is the regulatory status of pramlintide?
FDA approval. Symlin was approved under NDA 021332 on March 16, 2005, as a new molecular entity. AstraZeneca AB now holds the application [2]. The current DailyMed label was published on August 20, 2024 [1].
Market status. On November 18, 2026, Drugs@FDA listed all three Symlin products on the application as discontinued [2]. FDA's NDC Directory lists both SymlinPen packages with a marketing end date of January 31, 2027 [14].
Research-labeled products. FDA approval covers Symlin made under its approved application, not material sold under the pramlintide name. A research-use-only label does not make a product legal or safe for people. See research peptides and human-use risks and why research peptides have no dose.
Sport. The WADA 2026 Prohibited List does not name pramlintide or amylin analogs.
What is still unknown about pramlintide?
The published diabetes trials ran up to one year, plus one open-label extension [9]. The label reports no studies in end-stage renal disease or hepatic impairment, and limited pregnancy data [1]. The obesity trials were short and lost many participants before month 12 [13].
Frequently asked questions
Is pramlintide a peptide?
Yes. It is a 37-amino-acid synthetic peptide based on the sequence of human amylin.
How is pramlintide different from human amylin?
Three positions differ. Pramlintide has proline at positions 25, 28 and 29, where human amylin has alanine, serine and serine.
Is pramlintide approved for weight loss?
No. Symlin's only indication is add-on treatment in type 1 or type 2 diabetes for people using mealtime insulin.
Is Symlin still available in the United States?
Drugs@FDA lists all Symlin products as discontinued. FDA's NDC Directory gives January 31, 2027, as the marketing end date for both SymlinPen packages.
Is pramlintide the same as cagrilintide?
No. Both are amylin analogs, but cagrilintide is a separate, long-acting molecule developed by Novo Nordisk. Cagrilintide is not FDA-approved.
Is research-grade pramlintide FDA-approved?
No. FDA approval applies to Symlin made under its approved application. Material sold for laboratory research is not an approved medicine.
What to know now
- FDA approved it as Symlin on March 16, 2005, as an add-on to mealtime insulin in type 1 or type 2 diabetes.
- One-year trials showed modest HbA1c reductions and small weight losses versus placebo.
- The boxed warning covers severe hypoglycemia with insulin; nausea is the most common reaction.
- Drugs@FDA lists Symlin as discontinued, with a January 31, 2027 NDC marketing end date.
What we’re watching
- What happens to Symlin supply after the January 31, 2027 NDC marketing end date.
- Results from the registered dual-hormone automated insulin delivery study, NCT07914621.
- The Danish amylin migraine trials and FDA's review of long-acting amylin analogs such as cagrilintide.